Adult | Age
Item
1. adult males from 18 - 65 years
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Informed Consent
Item
2. written informed consent consistent with ich (international conference on harmonisation)/gcp (good clinical practice) and local legislation given prior to any study procedures
boolean
C0021430 (UMLS CUI [1])
Hepatitis C, Chronic | Hepatitis C Antibodies Immunoglobulin G Positive
Item
3. chronic hcv infection demonstrated by positive hcv igg antibody
boolean
C0524910 (UMLS CUI [1])
C0166049 (UMLS CUI [2,1])
C0020852 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
Hepatitis C virus genotype
Item
4. hcv genotype 1 which has to be confirmed by central laboratory test before visit 2
boolean
C1148363 (UMLS CUI [1])
Biopsy of liver Consistent with Hepatitis C | Liver Fibrosis Minimal | Liver Fibrosis Mild | Liver Cirrhosis | Ishak Score | Metavir score
Item
5. liver biopsy consistent with active hepatitis c virus (hcv) infection obtained within the last 24 months showing minimal to mild liver fibrosis and without cirrhosis (ishak or metavir grade <= 2)
boolean
C0193388 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C0019196 (UMLS CUI [1,3])
C0239946 (UMLS CUI [2,1])
C0547040 (UMLS CUI [2,2])
C0239946 (UMLS CUI [3,1])
C2945599 (UMLS CUI [3,2])
C0023890 (UMLS CUI [4])
C2986945 (UMLS CUI [5])
C3888527 (UMLS CUI [6])
HCV viral load
Item
6. hcv ribonucleic acid (rna) load greater than 100,000 iu rna per ml serum at screening
boolean
C1868902 (UMLS CUI [1])
Alcohol Abstinence Willing
Item
7. willing to abstain from alcohol during the screening, treatment and until completion of the study (visit 11)
boolean
C0678274 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Gender Contraceptive methods | Childbearing Potential Partner | Condoms, Male | Male sterilization | Hormonal contraception | Contraceptives, Oral, Hormonal | Contraceptive injection | Contraceptive implant | Intrauterine Devices
Item
1. males not using an adequate form of contraception (condom, sterilisation at least 6 months post operation) in case their partner is of childbearing potential and is not using an adequate form of contraception (hormonal contraceptives, oral or injectable/implantable, intra-uterine device (iud).
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0682323 (UMLS CUI [2,2])
C0009653 (UMLS CUI [3])
C0024559 (UMLS CUI [4])
C2985296 (UMLS CUI [5])
C0009907 (UMLS CUI [6])
C1656586 (UMLS CUI [7])
C1657106 (UMLS CUI [8])
C0021900 (UMLS CUI [9])
Chronic liver disease Etiology aspects | Virus Causing Hepatitis
Item
2. any other or additional plausible cause for chronic liver disease, including the presence of other viruses known or suspected to cause hepatitis
boolean
C0341439 (UMLS CUI [1,1])
C0015127 (UMLS CUI [1,2])
C0042776 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C0019158 (UMLS CUI [2,3])
Decompensated liver disease Evidence of | Ascites | Hypertension, Portal | Hepatic Encephalopathy
Item
3. evidence of decompensated liver disease: ascites, portal hypertension or hepatic encephalopathy
boolean
C4075847 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
C0003962 (UMLS CUI [2])
C0020541 (UMLS CUI [3])
C0019151 (UMLS CUI [4])
HIV Seropositivity | Hepatitis B surface antigen positive
Item
4. positive test for human immunodeficiency virus (hiv) or hepatitis b surface (hbs) antigen at screening
boolean
C0019699 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
Substance Use Disorders
Item
5. current alcohol or drug abuse, or history of the same, within the past twelve (12) months. all patients must abstain from alcohol from enrolment until completion of the study (visit 11).
boolean
C0038586 (UMLS CUI [1])
Comorbidity Requirement Therapeutic procedure | Comorbidity Requirement Pharmaceutical Preparations
Item
6. any concurrent medical illness or disease requiring treatment or concomitant medications
boolean
C0009488 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0009488 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
Malignant Neoplasms | Squamous cell carcinoma cured | Basal cell carcinoma cured
Item
7. history of malignancy (except for previously cured squamous cell or basal cell carcinoma)
boolean
C0006826 (UMLS CUI [1])
C0007137 (UMLS CUI [2,1])
C0679252 (UMLS CUI [2,2])
C0007117 (UMLS CUI [3,1])
C0679252 (UMLS CUI [3,2])
Investigational New Drugs
Item
8. usage of any investigational drug within thirty (30) days prior to enrolment or 5 halflives, whichever is longer; or the planned usage of an investigational drug during the course of the current study
boolean
C0013230 (UMLS CUI [1])
interferon | Ribavirin
Item
9. patients treated with interferon and/or ribavirin within 6 months prior to screening
boolean
C0733470 (UMLS CUI [1])
C0035525 (UMLS CUI [2])
Pharmacotherapy | Antiviral Therapy | Vaccination
Item
10. planned or concurrent usage of any other pharmacological therapy at screening, or during the trial period, including any antiviral therapy or vaccination
boolean
C0013216 (UMLS CUI [1])
C0280274 (UMLS CUI [2])
C0042196 (UMLS CUI [3])
Drug Allergy | Hypersensitivity Pharmaceutical Excipient
Item
11. known hypersensitivity to drugs or excipients
boolean
C0013182 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0015237 (UMLS CUI [2,2])
Laboratory Results
Item
12. patients with any one of the following laboratory values at screening:
boolean
C1254595 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement
Item
alanine transaminase (alt) or aspartate transaminase (ast) > 2.5 x upper limit of normal (uln) (at screening and during the last 3 months before screening demonstrated by at least 2 further determinations)
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
Serum total bilirubin measurement
Item
total bilirubin > 1x uln
boolean
C1278039 (UMLS CUI [1])
Alkaline phosphatase measurement
Item
alkaline phosphatase > 1.5x uln
boolean
C0201850 (UMLS CUI [1])
Prothrombin time | INR | Prothrombin time increased
Item
prothrombin time (inr, prolonged) > 1.5
boolean
C0033707 (UMLS CUI [1])
C0525032 (UMLS CUI [2])
C0151872 (UMLS CUI [3])
Platelet Count measurement
Item
platelet count < 100,000 / mm3
boolean
C0032181 (UMLS CUI [1])
Hemoglobin
Item
hemoglobin < 10.5 g/dl
boolean
C0019046 (UMLS CUI [1])
White Blood Cell Count procedure
Item
white blood cell count < 2,000 / mm3
boolean
C0023508 (UMLS CUI [1])
LABORATORY ABNORMALITIES Clinical Significance
Item
13. patients with any clinically significant laboratory abnormalities based on the investigator's medical assessment at screening
boolean
C1853129 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
Urinalysis Positive Drug abuse
Item
14. positive urine test for drug abuse at screening
boolean
C0042014 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
C0013146 (UMLS CUI [1,3])
Gilbert Disease
Item
15. patients with known gilbert's disease
boolean
C0017551 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
16. prior randomisation to active treatment with bilb 1941 zw into dose groups 3 - 9 of this trial, or previous re-treatment based on amendment 2. to support selection, centers will receive lists of the placebo patients of the previous dose levels, however, only for each center separately
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Protocol Compliance Unable
Item
17. inability to comply with the protocol
boolean
C0525058 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])